A new study from the University of Florida, published June 9 in Nature Metabolism, has found that glucosamine — a widely used joint pain supplement taken by millions — may significantly accelerate Alzheimer's disease progression. Researchers combined AI analysis of 12 years of electronic health records with post-mortem brain tissue studies and animal models to reach their findings.
Among patients already diagnosed with Alzheimer's, those taking glucosamine were 25% more likely to die within five years than non-users. People with mild cognitive impairment who took glucosamine also showed a 25% higher likelihood of progressing to full Alzheimer's disease. The biological mechanism: glucosamine crosses the blood-brain barrier and hyper-activates a protein sugar-tagging pathway that is already overactive in vulnerable brains.
About 8% of the 4,646 monitored dementia and MCI patients in the study were taking glucosamine supplements, a figure that underscores how widespread the habit is. The lead researcher, Dr. Ramon Sun, stressed the findings are an association — not proof of causality — but called for urgent clinical trials given the supplement's enormous global use.